International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

…, JF Rossi, S Nasta, K Yoshizaki… - Blood, The Journal …, 2018 - ashpublications.org
Castleman disease (CD) describes a group of heterogeneous hematologic disorders with
characteristic histopathological features. CD can present with unicentric or multicentric (MCD) …

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

N Nishimoto, T Kishimoto, K Yoshizaki - Annals of the rheumatic …, 2000 - ard.bmj.com
Interleukin 6 (IL6) is a pleiotropic cytokine with a wide range of biological activities. IL6 transgene
into mice gives rise to the abnormalities such as hyper-γ-globulinaemia, thrombocytosis…

IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review

A Ogata, Y Kato, S Higa, K Yoshizaki - Modern rheumatology, 2019 - academic.oup.com
Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid
arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from all …

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial

…, K Yoshizaki, N Miyasaka, K Yamamoto… - … : Official Journal of …, 2004 - Wiley Online Library
Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response,
inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in …

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and …

…, G Schürmann, N Nishimoto, K Yoshizaki… - Nature medicine, 2000 - nature.com
The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1–5) can bind to cells lacking the IL-6
receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R)(trans signaling) 5, 6, …

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease

K Yoshizaki, T Matsuda, N Nishimoto, T Kuritani… - 1989 - ashpublications.org
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma
cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma …

Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double‐blind …

…, B Hazleman, R Price, K Yoshizaki… - Arthritis & …, 2002 - Wiley Online Library
Yoshizaki and Nishimoto have received consulting fees and a research grant for other …
Yoshizaki and Nishimoto have received consulting fees and a research grant for other projects …

[HTML][HTML] Structure and function of a new STAT-induced STAT inhibitor

…, A Aono, N Nishimoto, T Kajita, T Taga, K Yoshizaki… - Nature, 1997 - nature.com
The signalling pathway that comprises JAK kinases and STAT proteins (for signal transducer
and activator of transcription) is important for relaying signals from various cytokines …

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

…, F Kodama, H Nakahara, K Hagihara, K Yoshizaki… - Blood, 2005 - ashpublications.org
… Kishimoto and K. Yoshizaki contributed to the conception of the study and worked as
coordinators of the clinical trial. KA made a histologic diagnosis of each patient's lymph node, which …

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

…, T Yamamura, J Azuma, N Nishimoto, K Yoshizaki… - Gastroenterology, 2004 - Elsevier
Background & Aims: Interleukin-6 (IL-6) regulates immune response and inflammation. We
carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and …